The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/267232
OUTSOURCING INSIGHTS REPORT If you want to learn more about the report or about how to participate, please contact Nigel Walker, managing director, or Salvatore Fazzolari, director of client services, at Nice Insight by sending an email to niceinsight.survey@thatsnice.com . N . W A L K E R S . F A Z Z O L A R I LIFESCIENCELEADER.COM MARCH 2014 16 If you want to learn more about the report or about how to participate, please contact Nigel Walker, managing director, or Salvatore Fazzolari, director of client services, at Nice Insight by sending an email to niceinsight.survey@thatsnice.com . N . W A L K E R S . F A Z Z O L A R I Survey Methodology: The Nice Insight Pharmaceutical and Biotechnology Survey is deployed to outsourc- ing-facing pharmaceutical and biotechnology executives on an annual basis. The 2013-2014 report includes responses from 2,337 participants. The survey comprises 240+ questions and randomly presents ~35 questions to each respondent in order to collect baseline information with respect to customer awareness and customer perceptions of the top 100+ CMOs and top 50+ CROs servicing the drug development cycle. Five levels of aware- ness from "I've never heard of them" to "I've worked with them" factor into the overall customer awareness score. The customer perception score is based on six drivers in outsourcing: Quality, Innovation, Regulatory Track Record, Affordability, Productivity, and Reliability. In addition to measuring customer awareness and perception information on specifi c companies, the survey collects data on general outsourcing practices and preferences as well as barriers to strategic partnerships among buyers of outsourced services. Both outsourcing and offshoring have shown their efficacy in cutting costs for pharma companies when it comes to solid dose manufacturing. Another potential development to emerge from reducing capital outlay on in-house manufacturing equipment and technolo- gies is a shift from tactical relationships for OSD projects toward more strate- gic, long-term agreements with manu- facturers. Interestingly, 65 percent of respondents who will outsource solid dosage manufacturing in 2014 expressed interest in a strategic partnership, which was considerably higher than the overall average of 48 percent interested in a stra- tegic partnership. However, the factors that carried the greatest influence on strategic partnership selection closely coincided between outsourcers of oral solid doses and the overall respondent group. They are experience, track record of success, and financial stability of the organization. L By K. Hammeke TRENDS IN OUTSOURCING SOLID DOSE MANUFACTURING IN 2014 Commercial Manufacturing Services To Be Outsourced In 2014 Outsourced Solid Dose Manufacturing Projects Assigned To Each Region Rank Of Industry Drivers When Selecting A Solid Dose Manufacturer Solid Dosage Forms Injectables Semi-Solids & Liquids Specialty Dosage Form Large Molecule API / Biologics Small Molecule API & Advanced Intermediates 55% 50% 44% 42% 37% 28% U.S. & Canada – 23% China – 15% Western Europe – 15% India – 13% Argentina & Brazil – 12% Eastern Europe & Turkey – 9% Korea – 5% Middle East – 4% Thailand & Vietnam – 4% 1 4 2 5 3 6 Quality Reliability Regulatory Track Record Productivity Affordability Innovation In general, respondents reported they would outsource fi nished dosage forms with a greater frequency than API manufacturing. 0 3 1 4 _ R e p o r t s _ O I . i n d d 2 0314_Reports_OI.indd 2 2 / 2 0 / 2 0 1 4 4 : 0 9 : 5 7 P M 2/20/2014 4:09:57 PM